Innovent Biologics Inc (6IB) - Total Assets
Based on the latest financial reports, Innovent Biologics Inc (6IB) holds total assets worth €37.35 Billion EUR (≈ $43.66 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Innovent Biologics Inc (6IB) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Innovent Biologics Inc - Total Assets Trend (2016–2025)
This chart illustrates how Innovent Biologics Inc's total assets have evolved over time, based on quarterly financial data. See Innovent Biologics Inc net assets for net asset value and shareholders' equity analysis.
Innovent Biologics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Innovent Biologics Inc's total assets of €37.35 Billion consist of 58.9% current assets and 41.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 46.4% |
| Accounts Receivable | €1.71 Billion | 4.6% |
| Inventory | €1.30 Billion | 3.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.88 Billion | 5.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Innovent Biologics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Innovent Biologics Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innovent Biologics Inc's current assets represent 58.9% of total assets in 2025, a decrease from 66.4% in 2016.
- Cash Position: Cash and equivalents constituted 46.4% of total assets in 2025, up from 36.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 5.0% of total assets.
Innovent Biologics Inc Competitors by Total Assets
Key competitors of Innovent Biologics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Innovent Biologics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.62 | 2.35 | 6.37 |
| Quick Ratio | 2.47 | 2.16 | 5.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €13.63 Billion | €5.90 Billion | €7.98 Billion |
Innovent Biologics Inc - Advanced Valuation Insights
This section examines the relationship between Innovent Biologics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.91 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | 72.9% |
| Total Assets | €37.35 Billion |
| Market Capitalization | $16.76 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Innovent Biologics Inc's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Innovent Biologics Inc's assets grew by 72.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Innovent Biologics Inc (2016–2025)
The table below shows the annual total assets of Innovent Biologics Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €37.35 Billion ≈ $43.66 Billion |
+72.89% |
| 2024-12-31 | €21.60 Billion ≈ $25.26 Billion |
+4.73% |
| 2023-12-31 | €20.63 Billion ≈ $24.12 Billion |
+17.28% |
| 2022-12-31 | €17.59 Billion ≈ $20.56 Billion |
+8.28% |
| 2021-12-31 | €16.24 Billion ≈ $18.99 Billion |
+37.25% |
| 2020-12-31 | €11.83 Billion ≈ $13.84 Billion |
+63.68% |
| 2019-12-31 | €7.23 Billion ≈ $8.45 Billion |
+18.29% |
| 2018-12-31 | €6.11 Billion ≈ $7.15 Billion |
+148.76% |
| 2017-12-31 | €2.46 Billion ≈ $2.87 Billion |
-12.73% |
| 2016-12-31 | €2.82 Billion ≈ $3.29 Billion |
-- |
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, a… Read more